Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Pregnant patients with vs without connective tissue diseases faced increased risks for adverse maternal and fetal outcomes, including maternal death, preterm labor, and hypertensive disorders.

Background: Connective tissue disorders (CTDs) are a heterogeneous group of ... myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), SH, gastroesophageal reflux disease (GERD), hypothyroidism, ...

Wearable devices are associated with a reduced risk for major adverse cardiovascular events and all-cause mortality in patients with ischemic heart disease. However, evidence of their effects on ...